GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2009

Biogen Idec Gains Ex-U.S. Rights to Acorda’s MS Therapy for $110M Up Front

  • Biogen Idec paid $110 million up front for rights outside the U.S. to Acorda Therapeutics’ MS drug, Fampridine-SR. The compound is currently under FDA review as a therapy to improve walking ability in patients with multiple sclerosis (MS) with a PDUFA date of October 22.  Acorda previously reported that the EMEA notified the firm that Fampridine-SR was eligible to be submitted for an MAA.

    The exclusive collaboration and license agreement calls for another $400 million in regulatory and sales milestones. Biogen Idec is responsible for regulatory activities and future clinical development of Fampridine-SR in non-U.S. markets. It will commercialize Fampridine-SR and any aminopyridine products developed under the agreement in these markets. Biogen Idec will make tiered, double-digit royalty payments based on non-U.S. sales.

    This transaction represents a sublicensing of an existing agreement between Acorda and Elan Pharma International. It also includes a supply agreement, under which Elan will continue to manufacture commercial supply of Fampridine-SR. Acorda will pay Elan 7% of the up-front and milestone fees that it receives.

    The amount Biogen Idec pays for products will reflect all amounts due from Acorda to Elan for non-U.S. sales, including royalties owed. The parties can also carry out future joint development activities under a cost-sharing arrangement.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?